The ocular pharmacokinetics of a new antibody (MIL60) against vascular endothelial growth factor ( VEGF) following subconjunctival injection in rats
10.3760/cma.j.issn.0254-5101.2018.12.010
- VernacularTitle:结膜下注射新型VEGF靶向抗体MIL60的眼局部药代动力学初步研究
- Author:
Qun WANG
1
;
Yan HUO
;
Jie ZHAO
;
Yifei HUANG
Author Information
1. 解放军总医院第三医学中心
- Keywords:
Pharmacokinetics;
VEGF;
Monoclonal antibody;
Targeted antibody;
Subconjunctival injection
- From:
Chinese Journal of Microbiology and Immunology
2018;38(12):938-942
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the ocular pharmacokinetics of a novel antibody, MIL60, tar-geting vascular endothelial growth factor ( VEGF) after subconjunctival injection. Methods After subcon-junctival injection of MIL60 in rabbits, aqueous humour, vitreous from both eyes and peripheral blood were collected of each rabbit to analyze the concentration of MIL60 with ELISA. Results After subconjunctival administration, MIL60 could penetrate into the injected eye′s anterior chamber and vitreous, and maintained at an effective concentration in the aqueous or vitreous for about 10. 7 or 6. 8 days. Moreover, MIL60 could be found in the uninjected eye. Conclusion After subconjunctival injection, MIL60 could maintain at a therapeutic concentration in injected eyes. The pharmacokinetics analysis of MIL60 might provide some basis and guidance for its application in humans in the near future.
